Drugs / GLWL-01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02377362 | Mar 2015 → Nov 2016 | type 2 diabetes mellitus | GLWL Research Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03896516 | Jun 2021 → Dec 2023 | alcohol-related disorders | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03274856 | Feb 2018 → Jun 2019 | Prader-Willi syndrome | GLWL Research Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03641417 | Feb 2019 → Mar 2020 | obesity disorder | University College, London | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLWL-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03641417 ↗ |
| Action | Inhibit | “GLWL-01 is a selective, reversible inhibitor of ghrelin O-acyltransferase (GOAT), the enzyme that converts UAG into AG.” PMID 35213714 ↗ May 2022 |
| Modality | Small molecule | “Small molecule inhibitor” NCT03641417 ↗ |
| Route | Oral | “Capsules administered orally, in 2 out of 3 periods” NCT02377362 ↗ |